Prosecution Insights
Prosecution Insights
16 pending office actions • 14 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 8 (50%) |
| §102 only | 3 (19%) |
| §112 only | 2 (12%) |
| No statute on record | 3 (19%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, MIKHAIL O'DONNEL | 1 | 56.8% | +41.6% |
| LEE, ANDREW P | 1 | 48.5% | +23.4% |
| GILL, RACHEL B | 1 | 65.6% | +27.7% |
| DEKARSKE, MADELINE MCGUIRE | 1 | — | — |
| BOESEN, AGNIESZKA | 1 | 68.1% | +21.9% |
| ENGLISH, CONNOR KENNEDY | 1 | 55.9% | +55.6% |
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.0% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
| FLINDERS, JEREMY C | 1 | 64.3% | +15.5% |
| CANELLA, KAREN A | 1 | 62.6% | +32.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18174015 | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients | CANELLA, KAREN A | 35d overdue |
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 26d overdue |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | FLINDERS, JEREMY C | 10d overdue |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 2d overdue |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | GILL, RACHEL B | 20d |
| 18332851 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ENGLISH, CONNOR KENNEDY | 26d |
| 18257808 | IMMUNOGENIC COMPOSITIONS | BOESEN, AGNIESZKA | 70d |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 83d |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1625 | 2 |
| 1691 | 1 |
| 1671 | 1 |
| 1622 | 1 |
| 1672 | 1 |
| 1638 | 1 |
| 1684 | 1 |
| 1643 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102 | Non-Final OA | 26d overdue | Pending | Nov 08, 2023 |
| 18388023 | METHODS FOR MITIGATING AND PREVENTING PROTEOSTASIS-BASED INJURIES | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 83d | Pending | Nov 08, 2023 |
| 18021792 | ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF | GILL, RACHEL B | 1671 | Other | Non-Final OA | 20d | Pending | Oct 10, 2023 |
| 18550500 | ANTIVIRAL PRODRUGS OF ETV AND FORMULATIONS THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | 33d | Pending | Sep 14, 2023 |
| 18257808 | IMMUNOGENIC COMPOSITIONS | BOESEN, AGNIESZKA | 1672 | §102 | Non-Final OA | 70d | Pending | Jun 15, 2023 |
| 18332851 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ENGLISH, CONNOR KENNEDY | 1625 | §102 | Non-Final OA | 26d | Pending | Jun 12, 2023 |
| 18256680 | A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN | SEAMAN, D MARGARET M | 1625 | §103 | Final Rejection | 60d overdue | Pending | Jun 09, 2023 |
| 18327110 | ENGINEERED CELLS AND METHODS OF USE | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | 2d overdue | Pending | Jun 01, 2023 |
| 18304993 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | FLINDERS, JEREMY C | 1684 | §103 | Non-Final OA | 10d overdue | Pending | Apr 21, 2023 |
| 18174015 | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients | CANELLA, KAREN A | 1643 | §103 | Final Rejection | 35d overdue | Pending | Feb 24, 2023 |
| 17923171 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | 65d | Pending | Nov 03, 2022 |
| 17918448 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | REYNOLDS, FRED H | 1658 | Other | Non-Final OA | 30d overdue | Pending | Oct 12, 2022 |
| 17768896 | EFFICIENT RNA SWITCHES AND RELATED EXPRESSION SYSTEMS | YAMASAKI, ROBERT J | 1657 | §103 | Non-Final OA | 22d | Pending | Apr 14, 2022 |
| 17716848 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | SHIN, DANA H | 1635 | Other | Non-Final OA | 8d overdue | Pending | Apr 08, 2022 |
| 17753138 | MONOCYCLIC AGONISTS OF STIMULATOR OF INTERFERON GENES STING | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §112 | Final Rejection | 14d | Pending | Feb 21, 2022 |
| 17419904 | THERAPEUTIC COMBINATIONS AS ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE | IVANOVA, SVETLANA M | 1627 | §103 | Final Rejection | 11d overdue | Pending | Jun 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial